Zimmer Biomet is reconstruction and ROSA robotics and one of the world's leading orthopedic suppliers.
Zimmer Biomet is one of the world's largest musculoskeletal health companies, with revenues of approximately $7.5 billion in 2025. The ROSA robotic surgical system — covering knee, hip, and spine applications — has reached over 1,200 installed units globally, making it the second-largest orthopedic robotics installed base. CEO Ivan Tornos's transformation strategy is focused on ROSA installed base acceleration, cementless knee portfolio expansion, and ambulatory surgery center penetration. The ZimVie spinoff of the company's spine and dental businesses in 2022 sharpened Zimmer Biomet's focus on the core reconstruction and robotics business.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Acquisitions and divestitures
• Marketing tactics
• Financial results
• Strengths and weaknesses
• Strategic directions
Table of Contents
1. Executive Summary
2. Company Overview and Business Model
3. Strategic Directions
4. Financial Results
5. SWOT Analysis
6. Technological Know-How and Key Products
7. Acquisitions and Divestitures
8. Marketing Tactics
9. Organization and Management
10. Appendix
List of Tables
Table 1. Zimmer Biomet — Key Financial Metrics 2023-2025
Table 2. Zimmer Biomet — Revenue by Segment 2023-2025
Table 3. Zimmer Biomet — Revenue by Geography 2023-2025
Table 4. Zimmer Biomet — SWOT Analysis
Table 5. Zimmer Biomet — Key Products and Platforms 2025
Table 6. Zimmer Biomet — M&A Activity 2020-2025
Table 7. Zimmer Biomet — Key Management 2025
Table 8. Zimmer Biomet — Strategic Priorities 2025-2030
